Obtained the exclusive distribution right of Amitin®, Jisuxing® and Cefobid® in Chinese mainland.
2015
The production base of Chongqing Hemony Pharmaceutical was put into operation.
2016
Merged and acquired Beishounin®, Hainiwei®, Haozhi® and Shiruida®.
2017
Merged and acquired Oribon®, Hainile®.
2018
Merged and acquired Melitor®, Lioresal® and Caltrate®.
2019
Merged and acquired Haiweibao®.
2020
Completed the production transfer of Caltrate®.
2022
Completed the production transfer of Haiweibao®.
2025
Obtained the exclusive distribution right of Luvox® in Chinese mainland;
Obtained the exclusive distribution right of Ovestin® in Chinese mainland;
Merged and acquired Haimoning®, Yilewei® and Haiyouxin®.
